Duke logo

NRG-BR002 for Oligometastatic Breast Cancer - Clinical Trial

What is the Purpose of this Study?

We are doing this study to compare any good or bad effects of delivering ablative local therapy to ALL known metastatic tumor sites, (even those that are not causing symptoms); in addition to the usual approach of intravenous or oral medications for treatment of breast cancer that has spread up to 4 body sites.

What is the Condition Being Studied?

Oligometastatic Breast Cancer

Who Can Participate in the Study?

Adult women with breast cancer which has spread who:
- Are not pregnant or nursing

Age Group
Adults

What is Involved?

If you agree to be in the study, you will:
- Be randomized (put into one of two groups by chance like a flip of a coin) and receive either:
Group 1 - usual treatment for metastatic breast cancer which is oral or intravenous medications and may include surgery, radiation, and other methods.
Group 2 - receive the usual treatment for metastatic breast cancer which is oral or intravenous medications PLUS ablative local therapy (SBRT or surgical resection) to all known metastatic sites.

Study Details

Full Title
NRG-BR002: A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
Principal Investigator
Radiation Oncologist
Protocol Number
IRB:PRO00061007
NCT:NCT02364557
Phase
Phase II/III
ClinicalTrials.gov
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698